Upstream Bio, Inc. (NASDAQ: UPB) is a Healthcare company (Biotechnology) with a market capitalization of $115M. The Maz Rating grades it against the other companies in its sector.
Upstream Bio, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.10, Upstream Bio, Inc. trades at 39.4x sales and 0.5x book value. Over the last twelve months it generated about $3M of revenue and a net loss of $168M. It runs a gross margin of 98.3%, an operating margin of -6116.0% and a net margin of -5712.3%. It shows return on equity of -57.1%, return on invested capital of -74.8% and a free cash flow yield of -146.3%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 20.45. Over the past 52 weeks the share price ranged from $2.00 to $33.68, with a beta of 1.39.
Upstream Bio, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.